Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Active not recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2

Conditions

Sarcoma 22Melanoma 6Histiocytoma, Malignant Fibrous 6Gastrointestinal Stromal Tumors 5Osteosarcoma 4Neoplasm Metastasis 4Gliosarcoma 4Neuroblastoma 3Hemangiosarcoma 3Chordoma 3Bone Neoplasms 3Wilms Tumor 2Triple Negative Breast Neoplasms 2Rhabdomyosarcoma 2Rhabdoid Tumor 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Nasopharyngeal Carcinoma 2Lymphoma 2Lung Neoplasms 2Liver Neoplasms 2Liposarcoma 2Head and Neck Neoplasms 2Glioblastoma 2Endometrial Neoplasms 2Carcinoma, Transitional Cell 2Carcinoma, Non-Small-Cell Lung 2Carcinoma, Hepatocellular 2Brain Neoplasms 2Bile Duct Neoplasms 2

Interventions

tazemetostat 6X-Rays 6Phantoms, Imaging 6Magnetic Resonance Spectroscopy 6Cyclophosphamide 6Specimen Handling 5Etoposide 5Carboplatin 5etoposide phosphate 4Temozolomide 4Nuclear Medicine Department, Hospital 4Granulocyte Colony-Stimulating Factor 4palbociclib 3Topotecan 3Thiotepa 3Sirolimus 3Mesna 3Melphalan 3Ifosfamide 3Filgrastim 3Busulfan 3Biopsy 3ulixertinib 2tipifarnib 2selpercatinib 2omburtamab I-131 2olaparib 2larotrectinib 2ivosidenib 2fludarabine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Rhabdoid Tumor × Ipilimumab × Sarcoma × Clear all
NCT05407441 2026-04-13

Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors

Dana-Farber Cancer Institute

Phase 1/2 Active not recruiting
49 enrolled
Sarcoma

Chordoma, Sarcoma, Rhabdoid Tumor

NCT04416568 2025-12-17

Study of Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative Cancers

Dana-Farber Cancer Institute

Phase 2 Active not recruiting
45 enrolled
Sarcoma

Chordoma, Sarcoma, Rhabdoid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡